Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01177007 · ClinicalTrials.gov registry record · Phase 2
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01177007 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 50 participants.
The verdict
NCT01177007, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study is an open label prospective trial of TheraSphere treatment for patients who have liver metastases who have failed or are intolerant to other systemic or liver directed therapies. Patients will be treated with TheraSphere at doses of 120 ± 10% Gy, and then followed for time to progression (TTP), safety, and overall survival.
Interventions
- DEVICE TheraSphere, Yttrium-90 glass Microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01177007
The ClinicalTrials.gov registry entry for NCT01177007 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TheraSphere, Yttrium-90 glass Microspheres is the first listed.
NCT01177007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01177007 about?
NCT01177007 is a clinical study titled "Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors". This study is an open label prospective trial of TheraSphere treatment for patients who have liver metastases who have failed or are intolerant to other systemic or liver directed therapies. Patients will be treated with TheraSphere at doses of 120 ± 10% Gy, and then followed for time to progression...
What is the current status of trial NCT01177007?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2010-09. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01177007?
The interventions under investigation include: TheraSphere, Yttrium-90 glass Microspheres (DEVICE).
Who is sponsoring clinical trial NCT01177007?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.